These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30171698)

  • 1. Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.
    Stockfleth E; Hofbauer GFL; Reinhold U; Popp G; Hengge UR; Szeimies RM; Brüning H; Anliker M; Hunger T; Dummer R; Ulrich C; Kenzelmann R; Surber C; French LE
    Br J Dermatol; 2019 Feb; 180(2):297-305. PubMed ID: 30171698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
    Szeimies RM; Bichel J; Ortonne JP; Stockfleth E; Lee J; Meng TC
    Br J Dermatol; 2008 Jul; 159(1):205-10. PubMed ID: 18476957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis.
    Farr MA; Joshi TP; Lewis DJ
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):433-434. PubMed ID: 34749552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of topical SR-T100 gel in treating actinic keratosis in Taiwan: A Phase III randomized double-blind vehicle-controlled parallel trial.
    Yang CC; Wong TW; Lee CH; Hong CH; Chang CH; Lai FJ; Lin SH; Chi CC; Lin TK; Yen H; Wu CH; Sheu HM; Lan CE
    J Dermatol Sci; 2018 Jun; 90(3):295-302. PubMed ID: 29530340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults.
    Sauder DN; Smith MH; Senta-McMillian T; Soria I; Meng TC
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3846-52. PubMed ID: 14638493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses.
    Ulrich C; Johannsen A; Röwert-Huber J; Ulrich M; Sterry W; Stockfleth E
    Eur J Dermatol; 2010; 20(4):482-8. PubMed ID: 20507841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.
    Pockros PJ; Guyader D; Patton H; Tong MJ; Wright T; McHutchison JG; Meng TC
    J Hepatol; 2007 Aug; 47(2):174-82. PubMed ID: 17532523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
    Rivers JK; Rosoph L; Provost N; Bissonnette R
    J Cutan Med Surg; 2008; 12(3):97-101. PubMed ID: 18544290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
    Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
    Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial.
    Pflugfelder A; Andonov E; Weide B; Dirschka T; Schempp C; Stockfleth E; Stratigos A; Krüger-Krasagakis S; Bauer J; Garbe C; Eigentler TK
    Br J Dermatol; 2015 Apr; 172(4):926-32. PubMed ID: 25124939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
    Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study.
    Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
    Stockfleth E; Kerl H; Zwingers T; Willers C
    Br J Dermatol; 2011 Nov; 165(5):1101-8. PubMed ID: 21517801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
    Pomerantz H; Hogan D; Eilers D; Swetter SM; Chen SC; Jacob SE; Warshaw EM; Stricklin G; Dellavalle RP; Sidhu-Malik N; Konnikov N; Werth VP; Keri J; Lew R; Weinstock MA;
    JAMA Dermatol; 2015 Sep; 151(9):952-60. PubMed ID: 25950503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.